News

Filter

Current filters:

USABristol-Myers Squibb

1 to 9 of 38 results

Fourth quarter Bristol-Myers Squibb results disappoint

Fourth quarter Bristol-Myers Squibb results disappoint

27-01-2015

Although the fourth quarter financial results from US drug major Bristol-Myers Squibb beat analyst estimates,…

Bristol-Myers SquibbFinancialPharmaceuticalUnited StatesUSA

Bristol-Myers to promote Caforio to CEO post; other appointments

Bristol-Myers to promote Caforio to CEO post; other appointments

21-01-2015

US pharma major Bristol-Myers Squibb yesterday announced a number of leadership changes approved by its…

BoardroomBristol-Myers SquibbManagementPharmaceuticalUSA

FDA approves Bristol-Myers Squibb’s Opdivo for advanced melanoma

FDA approves Bristol-Myers Squibb’s Opdivo for advanced melanoma

23-12-2014

The US Food and Drug Administration yesterday granted accelerated approval to US pharma major Bristol-Myers…

Bristol-Myers SquibbKeytrudaMerck & CoOncologyOpdivoPharmaceuticalRegulationUSA

Portola’s andexanet alfa reverses Eliquis anticoagulant effect

Portola’s andexanet alfa reverses Eliquis anticoagulant effect

17-12-2014

A Phase III clinical trial has found that Portola Pharmaceuticals' andexanet alfa reverses the effects…

andexanet alfaBristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalPortola PharmaceuticalsResearchUSA

US FDA requests additional data for Bristol-Myers Squibb's daclatasvir

US FDA requests additional data for Bristol-Myers Squibb's daclatasvir

27-11-2014

US pharma major Bristol-Myers Squibb has received a Complete Response Letter from the US Food and Drug…

Anti-viralsBristol-Myers SquibbdaclatasvirPharmaceuticalRegulationUSA

Bristol-Myers Squibb partners with Five Prime on immunotherapy combination trials

Bristol-Myers Squibb partners with Five Prime on immunotherapy combination trials

24-11-2014

US drug major Bristol-Myers Squibb and protein therapeutics specialist Five Prime Therapeutics are to…

BiotechnologyBristol-Myers SquibbFive Prime TherapeuticsOncologyOpdivoResearchUSA

Clear survival benefit for B-MS’ Opdivo in advanced melanoma patients

Clear survival benefit for B-MS’ Opdivo in advanced melanoma patients

17-11-2014

US drug major Bristol-Myers Squibb has announced results from a study comparing Opdivo (nivolumab) to…

Bristol-Myers SquibbOncologyOpdivoPharmaceuticalResearchUSA

Global melanoma market set to reach $3.6 billion by 2020

12-11-2014

The global melanoma therapeutics market was valued at $1.3 billion in 2013 and will expand at a compound…

Bristol-Myers SquibbEuropeJapanKeytrudaMarkets & MarketingMerck & CoOncologyOpdivoPharmaceuticalUSAYervoy

1 to 9 of 38 results

Back to top